LB PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (LBRX)

Q: What does CUSIP 50180M108 represent in this 13F holders report?

CUSIP 50180M108 is the security identifier for LBRX - LB PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held LBRX - LB PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share in Q3 2025?

53 institutional investors reported LBRX - LB PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share for Q3 2025. Use the holders table for investor-level position and value details.

CUSIP: 50180M108

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 28,742,016
Total 13F shares: 19,945,854
Share change: +19,945,854
Total reported value: $314,944,399
Price per share: $15.79
Number of holders: 53
Value change: +$314,944,399
Number of buys: 53

Quarterly Holders Quick Answers

What is CUSIP 50180M108?
CUSIP 50180M108 identifies LBRX - LB PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2025

Recent filing periods for CUSIP 50180M108:

Q1 2026 Q4 2025 Q3 2025

Top shareholders of LBRX - LB PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Marc L. Panoff	3/4/5	Senior Vice President, Finance	— mixed-class rows	100,767 mixed-class rows	$177,187	—	10 Sep 2025	3/4/5
Deep Track Capital, LP	13D/G	—	15%	3,352,804	—	$0	12 Sep 2025	13D/G
Ran Nussbaum	3/4/5	Director	— mixed-class rows	1,434,130 mixed-class rows	—	—	12 Sep 2025	3/4/5
Pontifax Management 4 G.P. (2015) Ltd.	3/4/5 13D/G	10%+ Owner	6.3% from 13D/G	1,411,681	—	—	12 Sep 2025	3/4/5 13D/G
Heather D. Turner	3/4/5	Chief Executive Officer, Director	— class O/S missing	971,828	—	—	10 Sep 2025	3/4/5
Vida Ventures GP III, L.L.C.	3/4/5	10%+ Owner	— class O/S missing	883,677	—	—	12 Sep 2025	3/4/5
Deep Track Special Opportunities Fund, LP	3/4/5	10%+ Owner	— class O/S missing	666,666	—	—	12 Sep 2025	3/4/5
Gad Soffer	3/4/5	Chief Business Officer	— class O/S missing	229,860	—	—	10 Sep 2025	3/4/5
Anna Eramo	3/4/5	Chief Medical Officer	— mixed-class rows	159,397 mixed-class rows	—	—	10 Sep 2025	3/4/5
Zachary Prensky	3/4/5	Director	— mixed-class rows	83,723 mixed-class rows	—	—	10 Sep 2025	3/4/5
Richard Anthony Silva	3/4/5	SVP, Technical Operations	— class O/S missing	80,899	—	—	10 Sep 2025	3/4/5
Robert R. Ruffolo	3/4/5	Director	— mixed-class rows	24,814 mixed-class rows	—	—	10 Sep 2025	3/4/5
J. Scott Garland	3/4/5	Director	— class O/S missing	22,449	—	—	10 Sep 2025	3/4/5
Rebecca Luse	3/4/5	Director	— class O/S missing	22,449	—	—	10 Sep 2025	3/4/5
Rekha Hemrajani	3/4/5	Director	— class O/S missing	22,449	—	—	10 Sep 2025	3/4/5
William P. Kane Jr.	3/4/5	Director	— class O/S missing	22,449	—	—	10 Sep 2025	3/4/5

Institutional Holders of LB PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (LBRX) as of Q3 2025

As of 30 Sep 2025, LB PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (LBRX) was held by 53 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 19,945,854 shares. The largest 10 holders included Deep Track Capital, LP, RA CAPITAL MANAGEMENT, L.P., TCG Crossover Management, LLC, Commodore Capital LP, Logos Global Management LP, JPMORGAN CHASE & CO, BlackRock, Inc., Balyasny Asset Management L.P., Vivo Capital, LLC, and JENNISON ASSOCIATES LLC. This page lists 53 institutional shareholders reporting positions in this security for the Q3 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2025 vs Q4 2025 Across Filers

Q4 2025 holders

Q3 2025 holders

Holder diff

-14

Investor	Q4 2025 Shares	Q3 2025 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q3 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.